
Visit us at the ASHG 2025 Annual Meeting to explore the latest innovations in single cell and spatial biology.
Hear from 10x Genomics R&D scientists about new single cell capabilities that enable massive scaling and cost efficiency, powerful single cell and spatial multiomic applications that unlock more insights from every sample, and flexible assay options that allow you to study your samples of interest.

Postdoctoral Scholar, Harvard University and the Broad Institute
As we navigate a century where transformative advances in biology and medicine will reshape the way we deliver human health, researchers need approaches that can keep up with the fast pace of their science. At 10x Genomics, we provide single cell, spatial, and in situ innovations that fuel scientific discoveries and drive exponential progress. Unravel highly complex systems, while bringing into focus the details that matter most.
Join our lunchtime Industry Education at ASHG to learn how Chromium Single Cell, Visium Spatial, and Xenium In Situ platforms from 10x Genomics can help you push the boundaries of your research. Our featured presenter is Kaili Fan, PhD, Postdoctoral Scholar, Kristin Ardlie Lab, Broad Institute of MIT and Harvard.
Additional 2025 technology updates from the 10x Genomics team will include:

Senior Scientist
10x Genomics
Single cell resolution at massive scale has become critical for advancing biomedical research, offering unprecedented insights into cellular heterogeneity, tissue architecture, and disease mechanisms. Landmark initiatives such as the Human Cell Atlas and the Billion Cells Project (Chan Zuckerberg Initiative, CZI) are driving an urgent demand for higher-throughput single cell technologies. Simultaneously, there is increasing need for platforms that can accommodate a wide range of clinically relevant sample types—including whole blood, fresh or frozen tissues, and formalin fixed paraffin embedded (FFPE) blocks—while enabling efficient sample collection, transport, storage, and batch processing. GEM-X Flex is currently the only platform that addresses all these demands, and enables profiling of up to 320,000 cells per well with the capability of 16-sample multiplexing.
Building on this robust foundation, we are excited to introduce GEM-X Flex v2—a major upgrade featuring enhanced robustness and dramatically expanded multiplexing capabilities. GEM-X Flex v2 supports recovery of up to 1 million cells per GEM lane (8 million per chip) and enables simultaneous processing of up to 384 multiplexed samples with streamlined workflow compatible with both tubes and 96-well plates, significantly enhancing scalability for large-cohort and longitudinal studies. In addition, GEM-X Flex allows flexible batching where customers can run a diverse number of sample number combos within a 96/384 set which greatly reduces pressure of sample processing. Customers also have the option to simply purchase additional gel beads and run the sample across multiple GEM-X Flex chip lanes to achieve up to 40M per kit plus additional cost of the extra gel beads. Our capability out scales competitions.
Along with the Flex v2 platform update, we also developed a compatible FFPE sample prep workflow that is xylene free and high-throughput just as the standard Flex v2 workflow. We would like to demonstrate our capability of profiling 24 FFPE blocks (4 replicates per block) with a 96-plex configuration. Here we compare the new workflow against OM SOP, as well as single-plex against multi-plex configurations.
The data demonstrates that with improved robustness, greater sample throughput, and reduced cost, GEM-X Flex v2 delivers higher-quality data and improved efficiency, making it a powerful, versatile platform for large-scale single cell transcriptomic studies in both academic and biopharma settings.

Scientist II
10x Genomics
The tumor microenvironment (TME) plays a critical role in cancer progression, immune evasion, and therapeutic resistance. However, the complex interplay and organization of its components cannot be captured using conventional bulk or dissociative single cell profiling methods. To better characterize how cellular and molecular features affect oncogenic processes, we applied Visium HD 3’ to a set of fresh frozen human cancer samples.
Visium HD 3’ allows the unbiased capture of polyadenylated analytes on a continuous spatially barcoded lawn of oligos. This gapless design enables precise profiling of finer anatomical features with high tissue coverage and single cell–scale resolution. Furthermore, Visium HD 3' enables spatial gene expression profiling and H&E staining from the same tissue section, mounted on a standard histology slide. Importantly, nuclei-based cell segmentation on H&E images can be incorporated to delineate individual cells and map spatial gene expression to histologically defined structures. The assay generates cDNA products compatible across short- and long-read sequencing platforms, supporting diverse applications, such as isoform and immune repertoire analysis in spatial context.
We profiled fresh frozen human breast and pancreatic cancer tissues to examine the spatial gene expression across the TME. Unsupervised clustering of segmented cells and gene expression mapping identified distinct compartments, including tumor-enriched regions (MUC1, EPCAM, ERBB2), stromal regions (MMP11, LUM, COL3A1), and immune cell infiltration regions (CD52, CXCR4, CD48) at single cell resolution. The stromal and tumor regions were separated at a cellular level with cell segmentation–based clustering.
To further evaluate cross-species resolution, we utilized Visium HD 3′ on a human–mouse xenograft model and successfully distinguished human cancer cells within the murine host. This underscores the assay’s capacity to resolve species-specific transcriptomes.
Collectively, our data show that Visium HD 3’ preserves tissue architecture and reveals spatial interactions often missed by dissociative approaches. By combining unbiased transcriptome-wide coverage with high-resolution spatial context, the assay enables deeper insights into gene expression heterogeneity, tissue organization, and tumor–immune dynamics in any species. These findings support its utility in biomarker discovery and the advancement of precision oncology.